| [1] |
ISON MG, GROSSI P, AST Infectious Diseases Community of Practice. Donor-derived infections in solid organ transplantation[J]. Am J Transplant, 2013, 13(Suppl 4):22-30. DOI: 10.1111/ajt.12095.
|
| [2] |
GRIM SA, CLARK NM. Management of infectious complications in solid-organ transplant recipients[J]. Clin Pharmacol Ther, 2011, 90(2):333-342. DOI: 10.1038/clpt.2011.90.
|
| [3] |
ALLEN UD, PREIKSAITIS JK, AST Infectious Diseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation[J]. Am J Transplant, 2013, 13(Suppl 4):107-120. DOI: 10.1111/ajt.12104.
|
| [4] |
SAN-JUAN R, MANUEL O, HIRSCH HH, et al. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. results of the ESGICH questionnaire-based cross-sectional Survey[J]. Clin Microbiol Infect, 2015, 21(6):604.e1-604.e9. DOI: 10.1016/j.cmi.2015.02.002.
|
| [5] |
SAN-JUAN R, COMOLI P, CAILLARD S, et al. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients[J]. Clin Microbiol Infect, 2014, 20(Suppl 7):109-118. DOI: 10.1111/1469-0691.12534.
|
| [6] |
LOWENBERG B. How I treat[M]. 3 ed. Washington: Blood Journal Press, 2018: 296-305.
|
| [7] |
COHEN JI. Epstein-Barr virus infection[J]. N Engl J Med, 2000, 343(7):481-492. doi: 10.1056/NEJM200008173430707
|
| [8] |
SWERDOW SH, WEBBER SA, CHADBUMA, et al. WHO classification of haematopoietic and lymphoid tissues[M]. Lyon: IARC Press, 2008: 343-349.
|
| [9] |
ALLEN U, HÉBERT D, MOORE D, et al. Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience[J]. Pediatr Transplant, 2001, 5(3):198-203. doi: 10.1034/j.1399-3046.2001.00059.x
|
| [10] |
HOSHIDA Y, LI T, DONG Z, et al. Lymphoproliferative disorders in renal transplant patients in Japan[J]. Int J Cancer, 2001, 91(6):869-875. doi: 10.1002/(ISSN)1097-0215
|
| [11] |
CHAN TS, HWANG YY, GILL H, et al. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment[J]. Clin Transplant, 2012, 26(5):679-683. DOI: 10.1111/j.1399-0012.2011.01593.x.
|
| [12] |
GREEN M, MICHAELS MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder[J]. Am J Transplant, 2013, 13(Suppl 3):41-54. DOI: 10.1111/ajt.12004.
|
| [13] |
DIERICKX D, HABERMANN TM. Post-transplantation lymphoproliferative disorders in adults[J]. N Engl J Med, 2018, 378(6):549-562. DOI: 10.1056/NEJMra1702693.
|
| [14] |
NALESNIK M, JAFFE R, REYES J, et al. Posttransplant lymphoproliferative disorders in small bowel allograft recipients[J]. Transplant Proc, 2000, 32(6):1213. doi: 10.1016/S0041-1345(00)01191-X
|
| [15] |
TSAO L, HSI ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders[J]. Arch Pathol Lab Med, 2007, 131(8):1209-1218. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Open J-Gate000002328336
|
| [16] |
EBV Work Group, Cincinnati Children' s Hospital Medical Center. Evidence-based clinical care guideline for management of EBV-associated post-transplant lymphoproliferative disease in solid organ transplant[EB/OL].[2019-12-26]. http://www.cincinnatichildrens.org/svc/alpha/h/healthpolicy/guidelines.htm.
|
| [17] |
CASTILLO JJ, BIBAS M, MIRANDA RN. The biology and treatment of plasmablastic lymphoma[J]. Blood, 2015, 125(15):2323-2330. DOI: 10.1182/blood-2014-10-567479.
|
| [18] |
EVENS AM, CHOQUET S, KROLL-DESROSIERS AR, et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era[J]. Am J Transplant, 2013, 13(6):1512-1522. DOI: 10.1111/ajt.12211.
|
| [19] |
苗芸, 于立新, 邓文锋, 等.国内报道移植后淋巴增殖性疾病的总结分析[J/CD].实用器官移植电子杂志, 2013, 1(5): 276-281.DOI: 10.3969/j.issn.2095-5332.2013.05.002.
MIAO Y, YU LX, DENG WF, et al. Post-transplant lymphoproliferative disorders: a summary analysis of reported cases in China[J/CD]. Pract J Organ Transplant (Electr Vers), 2013, 1(5): 276-281.DOI: 10.3969/j.issn.2095-5332.2013.05.002.
|
| [20] |
BUELL JF, GROSS TG, WOODLE ES. Malignancy after transplantation[J]. Transplantation, 2005, 80(2 Suppl):S254-S264. http://d.old.wanfangdata.com.cn/Periodical/zhxyx201710002
|
| [21] |
SWERDLOW SH. Pathology[M]//DHARNIDHARKA VR, GREEN M, WEBBER SA. Post-transplant lymphoproliferative disorders. Berlin and Heidelberg: Springer-Verlag, 2010: 89-104.
|
| [22] |
DIERICKX D, TOUSSEYN T, GHEYSENS O. How I treat posttransplant lymphoproliferative disorders[J]. Blood, 2015, 126(20):2274-2283. DOI: 10.1182/blood-2015-05-615872.
|
| [23] |
WADOWSKY RM, LAUS S, GREEN M, et al. Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR[J]. J Clin Microbiol, 2003, 41(11):5245-5249. doi: 10.1128/JCM.41.11.5245-5249.2003
|
| [24] |
PARKER A, BOWLES K, BRADLEY JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients-BCSH and BTS Guidelines[J]. Br J Haematol, 2010, 149(5):675-692. DOI: 10.1111/j.1365-2141.2010.08161.x.
|
| [25] |
PARKER A, BOWLES K, BRADLEY JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS guidelines[J]. Br J Haematol, 2010, 149(5):693-705. DOI: 10.1111/j.1365-2141.2010.08160.x.
|
| [26] |
SWERDLOW SH, CAMPO E, PILERI SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20):2375-2390.DOI: 10.1182/blood-2016-01-643569.
|
| [27] |
VAKIANI E, NANDULA SV, SUBRAMANIYAM S, et al. Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion[J]. Hum Pathol, 2007, 38(2):315-325. doi: 10.1016/j.humpath.2006.08.014
|
| [28] |
KRISHNAMURTHY S, HASSAN A, FRATER JL, et al. Pathologic and clinical features of Hodgkin lymphoma--like posttransplant lymphoproliferative disease[J]. Int J Surg Pathol, 2010, 18(4):278-285. DOI: 10.1177/1066896909338597.
|
| [29] |
ZIMMERMANN H, OSCHLIES I, FINK S, et al. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry[J]. Transplantation, 2012, 93(5):543-550. DOI: 10.1097/TP.0b013e318242162d.
|
| [30] |
MORSCIO J, DIERICKX D, NIJS J, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and Meta-analysis of 277 reported cases[J]. Am J Surg Pathol, 2014, 38(7):875-886. DOI: 10.1097/PAS.0000000000000234.
|
| [31] |
TAOKA K, NANNYA Y, YAMAMOTO G, et al. Progressive transition of Epstein-Barr virus associated lymphoproliferative disease subtypes with the development of lung cancer[J]. Am J Hematol, 2009, 84(9):600-603. DOI: 10.1002/ajh.21479.
|
| [32] |
TAKEHANA CS, TWIST CJ, MOSCI C, et al. (18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder[J]. Nucl Med Commun, 2014, 35(3):276-281. DOI: 10.1097/MNM.0000000000000050.
|
| [33] |
PITMAN SD, HUANG Q, ZUPPAN CW, et al. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically[J]. Am J Surg Pathol, 2006, 30(4):470-476. doi: 10.1097/00000478-200604000-00007
|
| [34] |
HART M, THAKRAL B, YOHE S, et al. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder[J]. Am J Surg Pathol, 2014, 38(11):1522-1529. DOI: 10.1097/PAS.0000000000000282.
|
| [35] |
LUSKIN MR, HEIL DS, TAN KS, et al. The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder[J]. Am J Transplant, 2015, 15(10):2665-2673. DOI: 10.1111/ajt.13324.
|
| [36] |
CRAIG FE, JOHNSON LR, HARVEY SA, et al. Gene expression profiling of Epstein-Barr virus-positive and-negative monomorphic B-cell posttransplant lymphoproliferative disorders[J]. Diagn Mol Pathol, 2007, 16(3):158-168. doi: 10.1097/PDM.0b013e31804f54a9
|
| [37] |
STUHLMANN-LAEISZ C, OSCHLIES I, KLAPPER W.Detection of EBV in reactive and neoplastic lymphoproliferations in adults-when and how?[J]. J Hematop, 2014, 7(4):165-170. doi: 10.1007/s12308-014-0209-0
|
| [38] |
KAPELUSHNIK J, ARIAD S, BENHARROCH D, et al. Post renal transplantation human herpesvirus 8-associated lymphoproliferative disorder and Kaposi' s sarcoma[J]. Br J Haematol, 2001, 113(2):425-428. doi: 10.1046/j.1365-2141.2001.02740.x
|
| [39] |
CHEN W, HUANG Q, ZUPPAN CW, et al. Complete absence of KSHV/HHV-8 in posttransplant lymphoproliferative disorders: an immunohistochemical and molecular study of 52 cases[J]. Am J Clin Pathol, 2009, 131(5):632-639. DOI: 10.1309/AJCP2T4IIIZKBHMI.
|
| [40] |
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients[J]. Am J Transplant, 2009, 9(Suppl 3):S1-S155. DOI: 10.1111/j.1600-6143.2009.02834.x.
|
| [41] |
TSAI DE, HARDY CL, TOMASZEWSKI JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients[J]. Transplantation, 2001, 71(8):1076-1088. doi: 10.1097/00007890-200104270-00012
|
| [42] |
GONZÁLEZ-BARCA E, DOMINGO-DOMENECH E, CAPOTE FJ, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease[J]. Haematologica, 2007, 92(11):1489-1494. doi: 10.3324/haematol.11360
|
| [43] |
CHOQUET S, LEBLOND V, HERBRECHT R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study[J]. Blood, 2006, 107(8):3053-3057. doi: 10.1182/blood-2005-01-0377
|
| [44] |
OERTEL SH, VERSCHUUREN E, REINKE P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD)[J]. Am J Transplant, 2005, 5(12):2901-2906. doi: 10.1111/j.1600-6143.2005.01098.x
|
| [45] |
KINCH A, BAECKLUND E, BACKLIN C, et al. A population-based study of 135 lymphomas after solid organ transplantation: the role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival[J]. Acta Oncol, 2014, 53(5):669-679. DOI: 10.3109/0284186X.2013.844853.
|
| [46] |
EVENS AM, DAVID KA, HELENOWSKI I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era[J]. J Clin Oncol, 2010, 28(6):1038-1046. DOI: 10.1200/JCO.2009.25.4961.
|
| [47] |
TRAPPE R, OERTEL S, LEBLOND V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial[J]. Lancet Oncol, 2012, 13(2):196-206. DOI: 10.1016/S1470-2045(11)70300-X.
|
| [48] |
TRAPPE RU, CHOQUET S, DIERICKX D, et al. International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial[J]. Am J Transplant, 2015, 15(4):1091-1100. DOI: 10.1111/ajt.13086.
|
Figures(1) / Tables(2)
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad: